Adjunctive Withania Somnifera (Ashwagandha) for Persistent Symptoms in People With Schizophrenia
Status:
Recruiting
Trial end date:
2022-02-01
Target enrollment:
Participant gender:
Summary
To determine whether a standardized extract of Withania somnifera will reduce psychopathology
scores (PANSS total score) in persons with schizophrenia. A secondary aim is to determine
whether WSE reduces measures of positive and negative symptoms (PANSS subscales) and stress
scores on the Perceived Stress Scale (PSS).
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Chengappa, K.N. Roy, MD University of California, Los Angeles
Collaborators:
Stanley Medical Research Institute University of Maryland University of Maryland, College Park